<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous

dc.authorid0000-0002-5079-4713
dc.contributor.authorÖzsütçü, Mustafa
dc.contributor.authorGülkılık, Gökhan
dc.contributor.authorAyıntap, Emre
dc.contributor.authorAltınışık, Muhammed
dc.contributor.authorDemirci, Göktuğ
dc.contributor.authorAras, Cengiz
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:33Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:33Z
dc.date.issued2013
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: To report 2 eyes of a patient which developed vitreomacular traction (VMT)1 month after intravitreal bevacizumab (IVB) injection. Materials and Methods: A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB. Results: Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively. Conclusion: In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy.
dc.identifier.citationÖzsütçü, M., Gülkılık, G., Ayıntap, E., Altınışık, M., Demirci, G. ve Aras, C. (2013). Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous. Case Reports in Ophthalmology, 4(1), 7-10. https://dx.doi.org/10.1159/000342873
dc.identifier.doi10.1159/000342873
dc.identifier.endpage10
dc.identifier.issn1663-2699
dc.identifier.issue1
dc.identifier.scopusqualityQ3
dc.identifier.startpage7
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1196
dc.identifier.urihttps://dx.doi.org/10.1159/000342873
dc.identifier.volume4
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofCase Reports in Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBevacizumab
dc.subjectDiabetic Macular Edema
dc.subjectPosterior Vitreous
dc.subjectVitreomacular Traction
dc.titleIntravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Demirci-Goktug 2013.pdf
Size:
803.69 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin/Full Text